CAR-T therapy is an innovative but expensive new cancer treatment that uses patients’ immune cells to fight against certain lymphoma cancers. It costs between $375,000 and $475,000.
The Certificate of Need Commission recommended Michigan limit the number of hospitals that could perform the CAR-T treatment and that hospitals be required to get approval from a state agency before being allowed to administer the therapy, according to The Heartland Institute’s Health Care News.
CON laws are intended to prevent healthcare providers from performing unnecessary procedures for monetary gain, and the Commission in this case argues the CAR-T therapy hasn’t been proven effective enough to justify the cost.
Legislators that vetoed the commission’s recommendation, however, argued the regulation would limit patients’ access to CAR-T and discourage other healthcare facilities from offering it, according to Health Care News.
Michigan state Sen. Curt Vanderwall, R-Ludington, told Health Care News he believes patients should be allowed to choose their CAR-T provider.
Read the full article here.
More articles on pharmacy:
Novant Health leaders talk Walgreens partnership goals for 2020
Sanofi recalls heartburn drug over cancer risks
Centura Health opens retail pharmacy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.